P3 Health Partners Inc.
No SEC Form 4 filings for $PIII in the last 30 days.
See all $PIII insider activity →P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 piii-20260810xexx991.htm EX-99.1 Document Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 H
P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. piii-20260630 0001832511 false 0001832511 2026-06-30 2026-06-30 0001832511 us-gaap:CommonClassAMember 2026-06-30 2026-06-30 0001832511 us-gaap:WarrantMember 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU
P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. piii-20260609 0001832511 false 0001832511 2026-06-09 2026-06-09 0001832511 us-gaap:CommonClassAMember 2026-06-09 2026-06-09 0001832511 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU
Over the past 7 days, alphai's AI scored 1 news story mentioning PIII (P3 Health Partners Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent PIII coverage spans financial news, corporate actions and market movers.
The 8-K discloses a profitability inflection in Q2 and a higher full-year adjusted EBITDA outlook, which can re-rate near-term expectations.
The 8-K discloses a balance-sheet/financing change: longer maturity plus higher PIK accrual, which can increase future debt burden and affect credit risk perception.
Share issuance authorization tied to outstanding warrants was approved, which can affect dilution expectations and warrant overhang.
Short-interest surge plus post-earnings optimism (EPS beat) raises near-term squeeze/volatility risk, even as the stock remains weak on trend.
Earnings/guidance-driven rerating is the core driver; the “no specific news” label is misleading versus the provided financial datapoints.
alphai scores every news story that mentions PIII with an AI model for sentiment and relevance, and aggregates insider trades from P3 Health Partners Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 piii-20260810xexx991.htm EX-99.1 Document Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 H
6 min readP3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. piii-20260630 0001832511 false 0001832511 2026-06-30 2026-06-30 0001832511 us-gaap:CommonClassAMember 2026-06-30 2026-06-30 0001832511 us-gaap:WarrantMember 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU
2 min readP3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. piii-20260609 0001832511 false 0001832511 2026-06-09 2026-06-09 0001832511 us-gaap:CommonClassAMember 2026-06-09 2026-06-09 0001832511 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU
2 min readP3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.
4 min readBiotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).
6 min readP3 Health Partners (PIII) has seen its price target reduced by 12.50% to $3.57. This adjustment reflects a change in analyst expectations for the company's future stock performance. Investors will likely monitor further developments and analyst reports regarding PIII.
3 min readImage source: The Motley Fool.Thursday, Aug. 14, 2025 at 4:30 p.m. ETChief Executive Officer - Aric CoffmanContinue reading ...
3 min readP3 Health Partners (PIII) delivered earnings and revenue surprises of -89.36% and -2.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readP3 Health Partners ( NASDAQ:PIII ) , a physician-led healthcare group focused on value-based care for Medicare Advantage members, reported results for Q2 FY2025 on August 14, 2025. The most notable news was a miss on both top- and bottom-line expectations: revenue ( GAAP ) came in slightly below ...
3 min readNEW YORK, July 22, 2025 ( GLOBE NEWSWIRE ) -- Wolf Haldenstein Adler Freeman & Herz LLP ( "Wolf Haldenstein" ) , a distinguished law firm with over 125 years of history, announces it is investigating claims on behalf of investors of P3 Health Partners, Inc. PIII ( "P3" or the "Company" ) .
2 min read
